Therefore, an inhibitor of AMPK signaling or its downstream substrate activation that prevents the differentiation of preadipocytes into adipocytes could be considered a potential treatment of obesity [41,42,43]. This evidence concerns the gene PRKAA1 and obesity due to melanocortin 4 receptor deficiency.